Instruction for use: Betamethasone + Calcipotriol (Betamethasonum+ Calcipotriolum)

Pharmacological group

Dermatotropin funds in combinations

Pharmacotherapy

Combination drug for the treatment of psoriasis. Calcipotriol is a synthetic analogue of the active metabolite of vitamin D. It causes inhibition of the proliferation of keratinocytes and accelerates their morphological differentiation. Betamethasone - GCS for external use; Has a local anti-inflammatory, anti-allergic, anti-edematous and antiproliferative effect. Has a stronger vasoconstrictive effect than other fluoride derivatives of GCS. When exposed to the skin, the edge accumulation of neutrophils is prevented, which leads to a decrease in exudation, production of cytokines, inhibition of migration of macrophages and ultimately to a decrease in the processes of infiltration and granulation.

Pharmacokinetics

Absorption of calcipotriol and betamethasone through the skin is about 1%. Systemic absorption of both components is extremely small. When combined, calcipotriol and betamethasone do not affect the pharmacokinetic properties of each other.

Indications

Psoriasis is vulgar.

Contraindications

Hypersensitivity, diseases accompanied by a violation of calcium metabolism; Viral, fungal and bacterial skin infections; Age to 18 years.

Carefully

Severe renal / hepatic insufficiency, pregnancy, lactation.

Dosing

Outwardly. Ointment is applied a thin layer on the affected skin areas 1 time per day. The maximum weekly dose should not exceed 100 g. The duration of the course of treatment is 4 weeks.

Side effect

On the part of the skin: itching, short-term skin irritation at the site of ointment application, dermatitis (including perioral and allergic contact), erythema, exacerbation of psoriasis, skin atrophy, telangiectasia, strep formation (especially with prolonged use), folliculitis, hypertrichosis , Hypopigmentation.

Systemic: hypercalcemia, suppression of adrenal cortex function.

Overdose

Symptoms: hypercalcemia; Suppression of the function of the pituitary-adrenal system with the development of reversible secondary adrenal insufficiency.

Treatment: withdrawal of the drug, symptomatic therapy.

Special instructions

It is not recommended to apply the product to the skin of the face. After applying the ointment, you should wash your hands thoroughly.

It is recommended to avoid the use of the drug on large areas of the skin, as well as under the occlusive dressing, to apply to the folds of the skin, as this increases the likelihood of systemic absorption of GCS.

When used in doses that exceed the recommended, it is possible to develop hypercalcemia, rapidly passing with a decrease in its dose or cancellation.

With prolonged use as a result of systemic absorption may be oppression of the hypothalamic-pituitary-adrenal system with the development of reversible secondary adrenal insufficiency or exacerbation of diabetes mellitus.

After prolonged use, the drug should be withdrawn gradually.